BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Basilea Pharmaceutica (BSLN.SW)'s European Marketing Authorization Application for ceftobiprole for the Treatment of Pneumonia Accepted for Review


10/5/2012 9:35:18 AM

BASEL, SWITZERLAND--(Marketwire - October 05, 2012) - Basilea Pharmaceutica AG / Basilea's European Marketing Authorization Application for ceftobiprole for the treatment of pneumonia accepted for review . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Basel, Switzerland, October 5, 2012 - Basilea Pharmaceutica Ltd. (SIX: BSLN) today reported that Basilea Pharmaceutica International Ltd. has received confirmation from European health authorities that the Marketing Authorization Application (MAA) for its novel investigational antibiotic ceftobiprole for the treatment of pneumonia in hospitals has been accepted for review under the decentralized procedure.

"We are very pleased that our ceftobiprole Marketing Authorization Application has been accepted for review and look forward to working closely with the European health authorities during the review process," stated Dr. Anthony Man, Chief Executive Officer of Basilea. "Basilea is committed to address the rising threat of bacterial resistance against current antibiotics. Ceftobiprole is a next generation antibiotic from the well-studied class of cephalosporin antibiotics with bactericidal activity against a broad spectrum of clinically relevant Gram-positive and Gram-negative pathogens that may cause pneumonia. Ceftobiprole has activity against Gram-positive bacteria, including methicillin- resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP) as well as Gram- negative pathogens, including Enterobacteriaceae and Pseudomonas aeruginosa."

The MAA submission is supported by two international, double-blind, controlled phase III studies assessing the efficacy and safety of first-line empiric ceftobiprole versus single or combination drug comparators to treat hospitalized community-acquired and hospital-acquired pneumonia.

About hospital-treated pneumonia

Community-acquired pneumonia is a common condition with up to 60% of the patients requiring hospital admission and intravenous antibiotics.[1] Hospital- acquired (nosocomial) pneumonia is one of the most common infections acquired in the hospital, accounting for approximately 25% of all intensive care unit (ICU) infections, and is associated with significant mortality.[2],[3] Prompt empiric intervention with an appropriate broad-spectrum antibiotic treatment is accepted as best medical practice. In both diseases the increasing incidence of resistant bacteria is a major concern.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and development operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd. the company focuses on innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to current treatment options.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward- looking statements contained herein as a result of new information, future events or otherwise.

This press release can be downloaded from www.basilea.com.

References

[1] Torres A and Rello J. Update in community-acquired and nosocomial pneumonia 2009. American Journal of Respiratory and Critical Care Medicine 2010; 181: 782-787.

[2] Torres A, Ferrer M and Badia JR. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clinical Infectious Diseases 2010; 51(S1): S48-S53.

[3] Muscedere JG, Day A and Heyland DK. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Clinical Infectious Diseases 2010; 51(S1): S120-S125.

Press release (PDF): http://hugin.info/134390/R/1646657/530673.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE

[HUG#1646657]


For further information, please contact:

Media Relations
Peer Nils Schroder, Ph.D.
Head Public Relations &
Corporate Communications
+41 61 606 1102
Email Contact

Investor Relations
Barbara Zink, Ph.D., MBA
Head Corporate Development

+41 61 606 1233
Email Contact


Read at BioSpace.com


   
Pneumonia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->